340B stakeholders raised concerns about May 12 draft guidance on the IRA Medicare Drug Price Negotiation Program's “manufacturer effectuation of the maximum fair price in 2026, 2027 and 2028,” among other things.
CMS Offers New Details on Medicare Drug Price Negotiations, 340B Advocates Raise Concerns About Impact on Program
The Centers for Medicare and Medicaid Services (CMS) released new details this week to help stakeholders navigate the Inflation Reduction [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
